| The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. | |
| | |
MedLine Citation:
|
PMID: 18088235 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Positron emission tomography (PET) is a noninvasive functional imaging technique that allows assessment of key biological processes important in cancer development and progression. It provides information complementary to conventional anatomic imaging, demonstrating utility in a range of cancer settings from diagnosis, biopsy guidance, tumor stratification and prognostication, and staging and surveillance of disease recurrence. Its ability to evaluate vital processes in tumor biology also makes it a potentially valuable and sensitive tool for assessing therapeutic response. The development of novel PET tracers and improvements in technology will only continue to augment the potential of PET and enhance its attractiveness as an instrument to facilitate drug development. This article will discuss the above issues, using the setting of sarcomas as an example. |
| | |
Authors:
|
Kenneth K Khamly; Rodney J Hicks; Grant A McArthur; David M Thomas |
Related Documents
:
|
17032175 - Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. 3497845 - Use of indium-111-labeled oc-125 monoclonal antibody in the detection of ovarian cancer. 18619385 - Imaging hodgkin and non-hodgkin lymphoma in the head and neck. 18716105 - Tumor staging of advanced esophageal cancer: combination of double-contrast esophagogra... 17032175 - Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. 1580955 - Jansky-bielschowsky variant disease: ct, mri, and spect findings. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert review of molecular diagnostics Volume: 8 ISSN: 1744-8352 ISO Abbreviation: Expert Rev. Mol. Diagn. Publication Date: 2008 Jan |
Date Detail:
|
Created Date: 2007-12-19 Completed Date: 2008-01-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101120777 Medline TA: Expert Rev Mol Diagn Country: England |
Other Details:
|
Languages: eng Pagination: 105-19 Citation Subset: IM |
Affiliation:
|
Division of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. ken.khamly@petermac.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Drug Design Humans Positron-Emission Tomography* Prognosis Sarcoma / drug therapy*, pathology, radionuclide imaging |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics.
Next Document: Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein i...